+44 (0) 1223 755950
+1 832 327 7413
Lerdelimumab
REQUEST MORE INFO
Catalogue No: abx831094
US$464.00
US$371.20
(Size: 100 µg)
Orders to United States ship from United States
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Lerdelimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TGFB2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Research Articles on TGFB2
| Target | TGFB2 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG4-ND |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 285985-06-0 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |